NMTRQ (9 Meters Biopharma) FCF Margin %: 0.00% (As of Mar. 2023)


What is 9 Meters Biopharma FCF Margin %?

9 Meters Biopharma NMTRQ -90.00% FCF Margin % is 0.00% as of Mar. 2023.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. 9 Meters Biopharma's Free Cash Flow for the three months ended in Mar. 2023 was $-9.75 Mil. 9 Meters Biopharma's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, 9 Meters Biopharma's FCF Margin % for the quarter that ended in Mar. 2023 was 0.00%.

As of today, 9 Meters Biopharma's current FCF Yield % is -411,300.00%.

The historical rank and industry rank for 9 Meters Biopharma's FCF Margin % or its related term are showing as below:


NMTRQ's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -85.21
* Ranked among companies with meaningful FCF Margin % only.

9 Meters Biopharma FCF Margin % Related Terms

9 Meters Biopharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for 9 Meters Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

9 Meters Biopharma FCF Margin % Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NMTRQ vs USRM, NOVNQ, ONCSQ: FCF Margin % Comparison

For the Biotechnology subindustry, 9 Meters Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

9 Meters Biopharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's FCF Margin % falls into.


9 Meters Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

9 Meters Biopharma's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-37.246/0
= %

9 Meters Biopharma's FCF Margin for the quarter that ended in Mar. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-9.75/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
9 Meters Biopharma (NMTRQ) has a FCF Margin % of 0.00% as of Mar. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 9 Meters Biopharma and its competitors.
Is 9 Meters Biopharma's FCF Margin % too high?
9 Meters Biopharma's current FCF Margin % is 0.00%.
How does 9 Meters Biopharma's FCF Margin % compare to USRM and NOVNQ?
9 Meters Biopharma's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 9 Meters Biopharma and its competitors. 9 Meters Biopharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 9 Meters Biopharma stock overvalued right now?
9 Meters Biopharma (NMTRQ) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For 9 Meters Biopharma (NMTRQ), the current FCF Margin % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

9 Meters Biopharma Business Description

Address 4509 Creedmoor Road, Suite 600, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. Its pipeline includes vurolenatide, a proprietary Phase 3 long-acting glucagon-like-peptide 1 (GLP-1) agonist for short bowel syndrome (SBS) and a robust pipeline of early-stage candidates for undisclosed rare diseases and/or unmet needs.